Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis (UC), is a key area of focus for Johnson & Johnson. Since introducing the first anti-tumor necrosis factor (TNF)-alpha therapy to the market in 1998 for the treatment of Crohn’s disease, we changed the IBD treatment paradigm and remain focused in this disease area.
Our unique clinical and research capabilities and expertise, combined with a track record of operational excellence and success, have fostered a robust, prioritized pipeline and
strategy for the future. With the introduction of biologics with new mechanisms of action (MOA) and targeted oral treatments, and investment in predictive biomarkers, Johnson & Johnson remains committed to developing differentiated treatments for both patients living with IBD and healthcare professionals.